{
    "Trade/Device Name(s)": [
        "CalprestNG",
        "EasyCal",
        "Calprest\u00aeNG"
    ],
    "Submitter Information": "Eurospital S.p.A.",
    "510(k) Number": "K191592",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160447"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "July 10, 2019",
    "Summary Letter Received Date": "June 14, 2019",
    "Submission Date": "June 11, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal Calprotectin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Stool",
        "Fecal extract"
    ],
    "Specimen Container(s)": [
        "EasyCal tube",
        "Primary stool container"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Colorimetric assay"
    ],
    "Methodologies": [
        "ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for CalprestNG fecal calprotectin ELISA assay with optional EasyCal pre-analytical stool extraction device",
    "Indications for Use Summary": "Quantitative ELISA for detecting fecal calprotectin to aid in diagnosis of Inflammatory Bowel Diseases (IBD, Crohn\u2019s disease and ulcerative colitis) and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings",
    "fda_folder": "Immunology"
}